Neoadjuvant immunotherapy improves outcomes in high-risk melanoma patients.

Published Date: 02 Mar 2023

High-risk melanoma patients who received the drug pembrolizumab before or after surgery to remove the cancer had a higher risk of developing melanoma than those who did not have a similar condition that eliminated cancer cells.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

BMTs that are "half-matched" are effective in treating severe sickle cell disease.

2.

Chemotherapy damage to non-cancer cells may be the cause of breast cancer recurrence.

3.

Lung cancer screening adherence rates decline annually after baseline screening

4.

Unlocking the potential of targeted therapies for multiple myeloma

5.

Why palliative care goes hand in hand with treatment for people with cancer: Q&A


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot